Perjeta (pertuzumab) 420 mg/14 mL

 150,000

Perjeta (pertuzumab) is an anticancer medication used to treat a specific type of breast cancer. It is a prescription-only medicine and must be administered under the supervision of a physician experienced in cancer treatment.

Collection

Key Information

  • Active Ingredient: Pertuzumab, a humanized IgG1 monoclonal antibody.
  • Form: A clear to slightly opalescent, colorless to pale yellow, sterile liquid concentrate for solution for infusion. Each single-use vial contains 420 mg of pertuzumab in 14 mL of solution.
  • Mechanism of Action: Perjeta is a targeted therapy that blocks the HER2 receptor protein on the surface of cancer cells, which helps stop tumor growth. It is often used in combination with another targeted treatment called Herceptin (trastuzumab) and chemotherapy.
  • Uses:
    • Metastatic Breast Cancer: Used in combination with trastuzumab and docetaxel for adults with HER2-positive metastatic or locally recurrent unresectable breast cancer who have not received prior treatment for their metastatic disease.
    • Early Breast Cancer: Used as part of a complete regimen with trastuzumab and chemotherapy both before surgery (neoadjuvant treatment) and after surgery (adjuvant treatment) for patients at high risk of recurrence.
  • Administration: The medication is given via intravenous (IV) infusion by a healthcare professional. An initial dose of 840 mg is followed every 3 weeks by a maintenance dose of 420 mg.
  • Manufacturer: It is a product of Roche.

Important Safety Information & Warnings

  • Heart Problems: Perjeta can cause serious heart problems, including symptomatic heart failure. Cardiac function must be evaluated before and during treatment.
  • Fetal Harm: The medication can cause birth defects or death to an unborn baby. Effective contraception must be used during treatment and for at least 7 months after the last dose.
  • Infusion Reactions: Serious infusion-related reactions, including fatal events, have been reported. Patients are monitored closely during and after infusions.
  • Common Side Effects: The most common adverse reactions (≥30%) when used in combination therapy include diarrhea, hair loss, fatigue, nausea, rash, and peripheral neuropathy.
Disclaimer: A healthcare professional should be consulted for medical advice, diagnosis, and treatment regarding this or any other medication.

Related Products

Ca Atra 10 mg (Tretinoin) Soft Gelatin Capsules

 10,000

Rebopag 25mg – Eltrombopag Tablets

 18,000